Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

• This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency.

• Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Center for Rheumatic Disease, Allergy, & Immunology
• Collaborators: Grifols Therapeutics Inc.; Grifols Therapeutics LLC
• Treatments: Immunoglobulins, Intravenous

Criteria

Inclusion Criteria:

• Adult (18 or older) with deficiency in one or more IgG subclasses with documented history of recurrent infections limited to upper or lower respiratory tract, urinary, and/or skin.

Exclusion Criteria:

• Patients with panhypogammaglobulinemia or selective IgA deficiency.